Pulmonary diseases are often considered locally, but the gut speaks. Dysbiosis and disrupted gut-lung crosstalk contribute to chronic inflammation, increased susceptibility to infection and delayed recovery in COPD, asthma, cystic fibrosis and post-COVID syndrome.

Multi-omics makes this hidden connection measurable and offers pulmonologists new biomarkers for prevention and therapy guidance.

The clinical problem

• COPD patients often exhibit gut dysbiosis that amplifies inflammation and exacerbates exacerbations(Yu et al., Front Cell Infect Microbiol 2025).
• Asthma often accompanies IBD or other intestinal problems, suggesting bidirectional crosstalk(Wang & Zhang, Chinese Med Cult 2025).
• Post-COVID patients report persistent shortness of breath, fatigue and autonomic disorders linked to microbiome immune dysfunction(Alves et al., ACS Infect Dis 2025).
• ARDS (acute respiratory distress syndrome) shows that microbiome metabolites co-direct the inflammatory cascade(Zhang et al., Front Immunol 2024).

Multi-omics insights into the gut-lung axis

1. SCFAs as key metabolites
   - Verma et al, ACS Pharmacol Transl Sci 2024: SCFAs improve lung function and reduce COPD exacerbations through anti-inflammation.
2. Post-COVID & lung microbiome
   - Fleming-van Eijk et al., Wiley 2025: post-COVID phenotypes show immune-crosstalk imbalance partially modifiable via gut interventions.
3. Respiratory microbiome & antibiotic resistance
   - Niculescu et al, Pathogens 2025: imbalance between gut and lung flora increases risk of resistant infections in chronic lung patients.
4. Probiotics & lung cancer prevention
   - Deepika et al, Front Oncol 2025: microbiome interventions may modulate immune responses relevant to lung cancer prevention and therapy.

Innovative solutions for the clinic

1. Pulmo-Gut Index
   - My InnerSelfie analyzes DNA, microbiome diversity and SCFA levels as predictors of lung function and exacerbation risk.
2. Post-COVID Recovery Scan
   - Multi-omics detects dysbiosis and immune activation that delay recovery after SARS-CoV-2.
3. Inflammation profiles
   - Objective markers of gut-driven inflammation that distinguish COPD or asthma clusters.
4. Therapy response personalization
   - Supports pulmonologists in deployment of inhaled steroids or immune modulating therapy.

Why My InnerSelfie is unique

• Multi-omics integration: DNA, metabolites and microbiome in one profile.
• Crosstalk focus: we visualize how gut and lung together affect inflammation and infection.
• Preventive precision: risks of exacerbations or post-COVID symptoms can be identified early.
• Additional tool for the physician: decisions remain in the hands of the pulmonologist; we enrich diagnostics.
• Tomorrow's care: innovative, preventive and always customized. Innovation of today becomes the standard of tomorrow - safe and scientifically based.

Key insights

• The gut-lung axis plays a central role in COPD, asthma, ARDS and post-COVID.
• SCFAs, dysbiosis and immune crosstalk are the missing links in chronic lung disease.
• My InnerSelfie offers pulmonologists biomarkers to personalize prevention and therapy.

Scientific references

• Yu X, Yu X, Guo X, et al. Respiratory diseases and the gut microbiota. Front Cell Infect Microbiol. 2025.
• Wang Y, Zhang Y. Gut-lung crosstalk based on COVID-19. Chinese Med Cult. 2025.
• Verma A, Bhagchandani T, Rai A, et al. SCFA and gut-lung axis in COPD and asthma. ACS Pharmacol Transl Sci. 2024.
• Alves MCS, Rego MS, Silva RCC, et al. Gut microbiota and COVID-19: gut-lung axis therapies. ACS Infect Dis. 2025.
• Deepika D, Alsharari ZD, Ahmad MF, et al. Gut-lung axis and prevention of lung cancer. Front Oncol. 2025.
• Niculescu AG, Mitache MM, Grumezescu AM. Respiratory microbiome and antibiotic resistance. Pathogens. 2025.
• Zhang DW, Lu JL, Dong BY, et al. Gut microbiota and ARDS inflammation. Front Immunol. 2024.
• Fleming-van Eijk LE, Tang G, et al. Post-COVID-19 condition and management. J Clin Pathol. Wiley. 2025.